EP2 receptor agonists
A compound selected from one of the following: or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP 2 receptor.
1 . A compound selected from one of the following:
or a salt, solvate, chemically protected form or prodrug thereof.
2 . (trans-2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 90% by weight is selected from one of the following forms:
or a salt, solvate, chemically protected form or prodrug thereof.
3 . 2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 80% by weight is in one of the following forms:
or a salt, solvate, chemically protected form or prodrug thereof.
4 . A method of making a compound according to claim 1 .
5 . (canceled)
6 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.
7 . A method of preparing a medicament comprising admixing a compound according to claim 1 , or a pharmaceutically acceptable salt thereof with a carrier.
8 - 14 . (canceled)
15 . A method of treating a condition which can be alleviated by the inhibtion of:
(i) human T-cell activation (proliferation);
(ii) the release of IL-2;
(iii) the release of TNF α ; or
(iv) the release of IF γ ; or
a method of treatnig a condition which can be alleviated by agonism of an EP 2 receptor, or
a method of treating graucoma, or dysmenorrhoea or pre-term labour, or
a method of treating a psoriasis, or an inflammatory lung disease,
which method comprises administering to a patient in need of treatment an effective amount of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof.
16 - 17 . (canceled)
18 . A method according to claim 15 , wherein the EP 2 receptor agonist is a compound selected from one of the following:
or a salt, solvate, chemically protected form or prodrug thereof.
19 . A method according to claim 15 , wherein the EP 2 receptor agonist is (trans-2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 90% by weight is selected from one of the following forms:
or a salt, solvate, chemically protected form or prodrug thereof.
20 . A method according to claim 15 , wherein the EP 2 receptor agonist is 2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 80% by weight is in one of the following forms:
or a salt, solvate, chemically protected form or prodrug thereof.